Get started
Author

Diana Beyer

Observed name: Beyer, Diana
OpenAlex ID: A5113694411
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria
2016 · Jan Menne, Dirk Eulberg, et al. · Nephrology Dialysis Transplantation · 207
PDF
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
2019 · Michael Steurer, Marco Montillo, et al. · Haematologica · 98
PDF
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
2021 · Meggy Suarez-Carmona, Anja Williams, et al. · Journal for ImmunoTherapy of Cancer · 85
PDF
Rational Design of Novel, Potent Small Molecule Pan-Selectin Antagonists
2007 · Remo Kranich, Anke S. Busemann, et al. · Journal of Medicinal Chemistry · 47
Effects of the Pan-selectin Antagonist Bimosiamose (tbc1269) in Experimental Human Endotoxemia
2008 · Florian B. Mayr, Christa Firbas, et al. · Shock · 15
Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.
2019 · Niels Halama, Ulrike Pruefer, et al. · Journal of Clinical Oncology · 9
Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males
2006 · Michael Meyer, Kai‐Michael Beeh, et al. · British Journal of Clinical Pharmacology · 9
PDF
Abstract CT117: Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
2020 · Niels Halama, Anja Williams, et al. · Cancer Research · 8
The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers
2007 · Michael Meyer, Diana Beyer, et al. · Biopharmaceutics & Drug Disposition · 5
Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
2018 · Niels Halama, Ulrike Pruefer, et al. · Journal of Clinical Oncology · 3
Abstract CT092: Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
2019 · Niels Halama, Ulrike Pruefer, et al. · Cancer Research
Abstract CT092: Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
2019 · Niels Halama, Ulrike Pruefer, et al. · Clinical Trials
Abstract B206: Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab
2019 · Niels Halama, Ulrike Prüfer, et al. · Cancer Immunology Research
Phosphorothiolate als Marker für Interferenzanalysen
2001 · Beyer, Diana · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
PDF
Works count: 14
Citation count: 486
H-index: 8
I10-index: 5
Year
Topic
Type